Royal Marsden Hospital
Head of radioisotope physics
Dr Glenn Flux is Head of Radioisotope Physics at the Royal Marsden Hospital and Institute of Cancer Research in Sutton, UK. His main research focus is on translational quantitative SPECT and PET imaging and its application to internal dosimetry for molecular radiotherapy. He has been involved in the development of imaging and dosimetry for clinical procedures including I-131 mIBG treatment of neuroblastoma and the treatment and palliation of bone metastases from prostate cancer with Re-186 HEDP and Ra-223. He has published over 100 peer reviewed articles and received research funding from national and international bodies. He is a founder member of the EANM Dosimetry Committee and is currently chair of the British Nuclear Medicine Society Molecular Radiotherapy committee.
The emergence and resurgence of radiotherapeutics for cancer treatment
Cancer treatment with radiopharmaceuticals is growing rapidly with many new radiotherapeutics either in development or early phase trials. Molecular radiotherapy and theragnostics promise to offer significant advances in cancer care and the market is expected to grow by 30% per annum for the foreseeable future. This presentation will review the potential impact of this expansion for industry, academia, and patient benefit.
EVEN MORE SEMINARS
Dr Youssef Mentias CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST
Ultrasound Thyroid Nodule Evaluation
Andy Rogers Nottingham University Hospitals
Interventional staff dose reduction: Gaining insight through new technology
Prof. Iris Grunwald Anglia Ruskin University, School of Medicine; Southend University Hospital
Pioneering treatment mechanical thrombectomy
Dr Ben Timmis 4ways Healthcare Ltd
How to manage x-ray reporting risk with fewer consultant radiologists
Dr Sam Hare Royal Free London NHS Foundation Trust
How I evaluate lung lesions for CT-guided biopsy?